The global Electrophoresis market is segmented on the basis of product, application, end user, and region. A number of factors, such as the growth in funding for research on electrophoresis techniques, increasing number of research collaborations between market players and academic institutions, increasing use of capillary electrophoresis (CE) with mass spectroscopy (MS), and growing focus on next-generation sequencing research are driving the growth of the electrophoresis market.
On the basis of product, the reagent segment accounted for the largest share of the global electrophoresis market. This is primarily attributed to the increasing demand for 2D electrophoresis for protein separation for various applications such as biomarker discovery and protein mapping. Over the years, genomic and proteomic technologies have gained significant importance in fields of clinical diagnosis and drug discovery and development. These are some of the key factors driving the growth of the electrophoresis market, and in turn supporting the growth of the electrophoresis reagents market during the forecast period.
Download PDF Brochure@
Based on application, the research segment accounted for the largest share of this market. Low cost and sensitive approach for DNA sequencing, the major role of electrophoresis in drug discovery, rising use of electrophoresis techniques as a result of growing importance of antibody research in the development of biotherapeutic are the major factors driving the use of electrophoresis, which has boosted the demand for research applications.
Request Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=434
Geographically, the global electrophoresis market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. In 2016, North America held the largest share of this market, and this is primarily attributed to the growing focus of stakeholders on research projects involving proteins, associated biomolecules, and genes; stringent regulatory requirements regarding pharmaceutical manufacturing necessitating quality control and process validation processes; rising focus on the development of structure-based drug designs; and growing research activities in the fields of Genomics and proteomics.
The major players operating in this market are Bio-Rad Laboratories (U.S.), GE Healthcare (U.S.), Thermo Fisher Scientific Inc. (U.S.), Danaher Corporation (U.S.), Agilent Technologies (U.S.), Merck Millipore (U.S.), PerkinElmer, Inc. (U.S.), QIAGEN N.V. (Netherlands), Lonza Group Ltd. (Switzerland), Shimadzu Corporation (Japan), Harvard Bioscience, Inc. (U.S.), Sebia Group (U.K.), and C.B.S. Scientific Company, Inc. (U.S.).